Trial Profile

A double-blind randomized extension study to assess the long-term efficacy and safety of linzagolix in subjects with endometriosis-associated pain

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Linzagolix (Primary) ; Estradiol/norethisterone
Indications Endometriosis; Pelvic pain
Focus Therapeutic Use
Acronyms Edelweiss 3 extension; EDELWEISS 6
Sponsors Kissei Pharmaceutical; ObsEva

Most Recent Events

27 Mar 2024 Status changed from active, no longer recruiting to completed.
02 Feb 2023 This trial has been completed in Czech Republic according to European Clinical Trials Database record.
20 Jan 2023 This trial has been completed in Hungary (Date of the global end of the trial: 16-Dec-2022), according to the European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com